Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report

[1] Carteni G(2006)Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial Oncologist 11 841-848

[2] Bordonaro R(1993)The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 570-579

[3] Giotta F(2001)Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165-176

[4] Cella DF(2004)Safety of intravenous and oral biphosphonates and compliance with dosing regimens Oncologist 9 28-37

[5] Tulsky DS(2007)The use of bisphosphonates in elderly cancer patients Oncologist 12 62-71

[6] Gray G(1996)Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group N Engl J Med 335 1785-1791

[7] Coleman RE(1998)Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group J Clin Oncol 16 2038-2044

[8] Conte P(2000)Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease J Bone Joint Surg Am 82 642-651

[9] Guarnieri V(2001)Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 377-387

[10] Gridelli C(2003)Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double blind, randomized trial. The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 3150-3157

[1] Carteni G(2006)Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial Oncologist 11 841-848

[2] Bordonaro R(1993)The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 570-579

[3] Giotta F(2001)Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165-176

[4] Cella DF(2004)Safety of intravenous and oral biphosphonates and compliance with dosing regimens Oncologist 9 28-37

[5] Tulsky DS(2007)The use of bisphosphonates in elderly cancer patients Oncologist 12 62-71

[6] Gray G(1996)Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group N Engl J Med 335 1785-1791

[7] Coleman RE(1998)Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group J Clin Oncol 16 2038-2044

[8] Conte P(2000)Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease J Bone Joint Surg Am 82 642-651

[9] Guarnieri V(2001)Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 377-387

[10] Gridelli C(2003)Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double blind, randomized trial. The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 3150-3157